These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 10529161)

  • 1. Treatment of rheumatoid arthritis with the dopamine agonist quinagolide.
    Eijsbouts A; van den Hoogen F; Laan RF; Hermus RM; Sweep FC; van de Putte L
    J Rheumatol; 1999 Oct; 26(10):2284-5. PubMed ID: 10529161
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of mania after long-term use of quinagolide.
    Vinkers DJ; van der Wee NJ
    Gen Hosp Psychiatry; 2007; 29(5):464. PubMed ID: 17888817
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of macroprolactinomas with quinagolide (Norprolac)].
    Tabarin A; Catargi B
    Ann Endocrinol (Paris); 1997; 58(2):87-94. PubMed ID: 9239226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of quinagolide in the treatment of a patient with hypophyseal resistance to thyroid hormones].
    De Luis DA; Lahera M; Botella JI; Valero MA; Varela C
    An Med Interna; 2001 May; 18(5):259-61. PubMed ID: 11496561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypogonadism secondary to hyperprolactinaemia: successful treatment but adverse consequences.
    Narayanan RP; Bujawansa S; Qureshi Z; Rimmer M; Heald A
    Exp Clin Endocrinol Diabetes; 2012 May; 120(5):311-3. PubMed ID: 22441722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheumatoid arthritis accompanied by Parkinson disease.
    Kogure T; Tatsumi T; Kaneko Y; Okamoto K
    J Clin Rheumatol; 2008 Jun; 14(3):192-3. PubMed ID: 18525447
    [No Abstract]   [Full Text] [Related]  

  • 7. Tissue-polypeptide-specific antigen in SLE patients treated with low doses of quinagolide.
    Hrycek A; Kokocińska D; Kośmider J; Konieczny B
    Lupus; 2003; 12(2):149-52. PubMed ID: 12630763
    [No Abstract]   [Full Text] [Related]  

  • 8. Pilot study on the treatment of cyclical mastodynia with Quinagolide.
    Ioannidou-Mouzaka L; Niagassas M; Galanos A; Kalovidouris A
    Eur J Gynaecol Oncol; 1999; 20(2):117-21. PubMed ID: 10376428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute complications of dopamine agonist treatment for macroprolactinoma - how uncommon?
    Nadesapillai S; Balcere I; Kaye AH; Tress BM; Colman PG
    J Clin Neurosci; 2004 Nov; 11(8):825-8. PubMed ID: 15519856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of messenger RNA for transforming growth factor-beta1 and for transforming growth factor-beta receptors in peripheral blood of systemic lupus erythematosus patients treated with low doses of quinagolide.
    Hrycek A; Kusmierz D; Dybała T; Swiatkowska L
    Autoimmunity; 2007 Feb; 40(1):23-30. PubMed ID: 17364494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Problematic gambling on dopamine agonists: Not such a rarity.
    Grosset KA; Macphee G; Pal G; Stewart D; Watt A; Davie J; Grosset DG
    Mov Disord; 2006 Dec; 21(12):2206-8. PubMed ID: 17013907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinagolide effects in normoprolactinemic galactorrhea.
    Zervoudis S; Iatrakis G; Galazios G; Liberis V; Tsikouras P; Koutlaki N; Mastorakos G; Badiu C
    Breast J; 2014; 20(2):221-3. PubMed ID: 24405300
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
    Kars M; Pereira AM; Smit JW; Romijn JA
    Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists.
    Kontogeorgos G; Horvath E; Kovacs K; Coire C; Lloyd RV; Scheithauer BW; Smyth HS
    Acta Neuropathol; 2006 Jan; 111(1):46-52. PubMed ID: 16328513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma.
    Demartini B; Ricciardi L; Ward A; Edwards MJ
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):471. PubMed ID: 24078717
    [No Abstract]   [Full Text] [Related]  

  • 16. CV 205-502: a more effective dopamine agonist in the treatment of acromegaly?
    Jaquet P
    Eur J Endocrinol; 1995 May; 132(5):557-8. PubMed ID: 7749495
    [No Abstract]   [Full Text] [Related]  

  • 17. Prolactin excess: treatment and toxicity.
    Gillam MP; Fideleff H; Boquete HR; Molitch ME
    Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():108-14. PubMed ID: 16456489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological gambling associated with dopamine agonist use in restless legs syndrome.
    Quickfall J; Suchowersky O
    Parkinsonism Relat Disord; 2007 Dec; 13(8):535-6. PubMed ID: 17270485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary study of dopamine-mediated prolactin inhibition in generalised social phobia.
    Condren RM; Sharifi N; Thakore JH
    Psychiatry Res; 2002 Aug; 111(1):87-92. PubMed ID: 12140123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity.
    Eijsbouts AM; van den Hoogen FH; Laan RF; Sweep CG; Hermus AR; van de Putte LB
    Ann Rheum Dis; 2005 Mar; 64(3):433-7. PubMed ID: 15319231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.